A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Seviteronel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Innocrin Pharmaceuticals; Viamet Pharmaceuticals
- 20 Sep 2017 Planned number of patients changed from 154 to 200.
- 20 Sep 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2018.
- 20 Sep 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.